SNDX - NASDAQ
Syndax Pharmaceuticals, Inc.
$18.34
-2.7%Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
At a Glance
Live Snapshotsndx
Other Current Liabilities
Last Annual Value
103.06M
3-Year CAGR
151%
5-Year CAGR
94%
10-Year CAGR
60%
Syndax Pharmaceuticals, Inc. Competitors Analysis of Other Current Liabilities
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | 103.06M | 42.1% | 75.3% | 35.0% | |
 Zenas BioPharma, Inc. NASDAQ:ZBIO | 54.30M | 119.7% | N/A | N/A | |
 Nektar Therapeutics NASDAQ:NKTR | 22.27M | 58.9% | 7.2% | -3.7% | |
 ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | 13.26M | 9.0% | 22.6% | N/A | |
 Atai Beckley Inc. NASDAQ:ATAI | 11.11M | 116.1% | 111.1% | N/A | |
 Inhibrx Biosciences, Inc. NASDAQ:INBX | 18.08M | 40.6% | 13.4% | 35.7% | |
 Amylyx Pharmaceuticals, Inc. NASDAQ:AMLX | 17.91M | -24.1% | 33.1% | N/A | |
 Sana Biotechnology, Inc. NASDAQ:SANA | 62.12M | 38.3% | -3.6% | N/A | |
 Relay Therapeutics, Inc. NASDAQ:RLAY | 14.11M | 94.9% | 70.2% | N/A |
Syndax Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your SNDX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.